ADXS Stock Overview
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States.
Advaxis, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.15|
|52 Week High||US$44.80|
|52 Week Low||US$1.02|
|1 Month Change||-42.67%|
|3 Month Change||-36.01%|
|1 Year Change||-94.68%|
|3 Year Change||-89.70%|
|5 Year Change||-99.96%|
|Change since IPO||-100.00%|
Recent News & Updates
|ADXS||US Biotechs||US Market|
Return vs Industry: ADXS underperformed the US Biotechs industry which returned -30% over the past year.
Return vs Market: ADXS underperformed the US Market which returned -23.1% over the past year.
|ADXS Average Weekly Movement||15.7%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: ADXS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: ADXS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer.
Advaxis, Inc. Fundamentals Summary
|ADXS fundamental statistics|
Is ADXS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ADXS income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jul 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-8.94|
|Net Profit Margin||-6,494.80%|
How did ADXS perform over the long term?See historical performance and comparison